Clinical trials: Vehicle, open to volunteers
Open Angle Glaucoma, Primary Open Angle Glaucoma
Topical Insulin for Glaucoma (TING2)
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma.
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma
- Trial name
- NCT07619482
- Testing
- EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Dry Eye
A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease
This is a Phase 2 clinical study designed to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution compared with placebo in participants with dry eye disease. The study will enroll adults with dry eye disease.
- Trial name
- NCT07625124
- Testing
- RCI001 Ophthalmic Solution
- Volunteers
- 200 people
- Sponsor
- Rudacure
Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).
- Conditions
- Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD)
- Trial name
- CLEAR-AD1 (NCT06855745)
- Testing
- zabalafin
- Where
- 12 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Alphyn Biologics
Stress, Sleep
Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress.
This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day…
- Conditions
- Stress, Sleep, Cognition, Nutrition
- Trial name
- NCT07369869
- Testing
- Proprietary 'active' composition 1, Proprietary 'active' composition 2, Inactive control supplement
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Northumbria University
Delirium
Melatonin for Treatment of Delirium in Critically Ill Adult Patients
The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients.
- Trial name
- DELIRE-ICU (NCT05713877)
- Testing
- Melatonin
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Drug Related Side Effects and Adverse Reactions, Infusion Reactions
Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform
Protocol PICO-RWE-001: The goal of this observational study is to evaluate the kinetic safety and tolerability of an investigational intravenous micellar delivery platform.
- Trial name
- NCT07609069
- Testing
- PIV-850 (850-picometer Dual-NCE Acidic Matrix), Legacy Heterogeneous Payload (Micellar Vehicle)
- Where
- United States
- Volunteers
- 625 people
- Sponsor
- PICO IV, Inc.
Healthy Volunteers (HV), Skin Irritation
Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use
This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers.
- Trial name
- EV-MELSAFE (NCT07707986)
- Testing
- Exosome-Containing Liquid, Vehicle Liquid
- Where
- Kazakhstan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- West Kazakhstan Marat Ospanov Medical University
Epiphora
Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)
This study tests whether a very low concentration of atropine eye drops (0.005%) reduces excessive tearing (epiphora) in adults.
- Trial name
- NCT07816224
- Testing
- Atropine sulfate ophthalmic solution 0.005%, Vehicle arm
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rehan Ahmed
Parkinson Disease
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
- Trial name
- NCT06466525
- Testing
- LBT-3627
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Longevity Biotech Australia Pty Ltd (subsidiary)
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
Irritant Contact Dermatitis
Glycyrrhetinic Acid and Acute Irritant Dermatitis
Irritant dermatitis is one of the most common inflammatory skin disorders, caused by exposure to external substances that induce inflammation and immune activation.
- Trial name
- NCT07286487
- Testing
- SLS induced irritation, No Treatment, Low Dose Glycyrrhetinic Acid Formulation
- Where
- Croatia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Split, School of Medicine
Parkinson Disease
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
- Trial name
- NCT07280299
- Testing
- Low Dose GT-02287, High Dose GT-02287
- Volunteers
- 111 people
- Sponsor
- Gain Therapeutics, Inc.
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Atopic Dermatitis
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
It is a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial to evaluate the efficacy of QLM3003 ointment at week 8 based on the primary endpoint (EASI 75) and key secondary endpoint…
- Trial name
- NCT06880276
- Testing
- 1.5% QLM3003 ointment, 2% QLM3003 ointment
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Amputation
Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.
The study will enroll 20 adults ages 18-75 with a transtibial amputation with mature residual limbs who are ambulatory prosthesis users.
- Trial name
- NCT04839497
- Testing
- Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Major Extremity Trauma Research Consortium
Dry Eye Disease, Dry Eye
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for…
- Conditions
- Dry Eye Disease, Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes
- Trial name
- CAMOMILE-2 (NCT06903611)
- Testing
- CAM-101, Vehicle Control
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Cambium Bio Limited
NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.
- Trial name
- NCT06804811
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 78 sites in Argentina, Austria and 12 more
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
Dry Eye
JN002 for the Treatment of Dry Eye Disease
This is a first-in-human, single-center, randomized, double-blind, placebo-controlled clinical trial designed to:·Evaluate the efficacy of JN002 Ophthalmic Solution in treating dry eye disease (DED)·Assess the safety of JN002…
- Trial name
- NCT07245017
- Testing
- JN002 Ophthalmic Solution (0.05 mg/mL), JN002 Ophthalmic Solution (0.1 mg/mL)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Parkinson Disease
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered…
- Trial name
- LoCaMoTE-PD (NCT07005180)
- Testing
- HBI-002
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
EGFR Inhibitor-associated Rash
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy.
- Trial name
- NCT06830863
- Testing
- ATR04-484, Vehicle
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Azitra Inc.